Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETX-636 in Advanced Solid Tumors (Phase 1/2, First-in-Human, China)
CTR20255260Phase 2Active
- Sponsor
- ENSEM Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ETX-636 in Nonhematologic neoplasms, sponsored by ENSEM Therapeutics. Started Jan 2026; status: active.
02
Drugs
ETX-636
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20255260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255260.